The epidermal growth factor receptor variant <scp>III</scp> (<scp>EGFR</scp>v<scp>III</scp>): where wild things are alteredHui Gan, Terrance G. Johns|FEBS Journal|2013Cited by 357
Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the ReceptorTerrance G. Johns, Andrew M. Scott|Journal of Biological Chemistry|2004Cited by 145
Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor ActivityRushika M. Perera, Terrance G. Johns|Clinical Cancer Research|2005Cited by 103
The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and HeterodimerizationTerrance G. Johns, Frank B. Furnari|Clinical Cancer Research|2007Cited by 84
Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-METSameer A. Greenall, Terrance G. Johns|PLoS ONE|2012Cited by 30